QED Therapeutics, a BridgeBio Company
Clinical trials sponsored by QED Therapeutics, a BridgeBio Company, explained in plain language.
A biotech subsidiary of BridgeBio developing targeted therapies for genetic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study tracks growth in kids with rare bone disorder Results expected Oct 2026 (estimated) May already have reported ↗
- Could a daily pill boost growth in kids with hypochondroplasia? Results expected Jan 2027 (estimated) May already have reported ↗
-
Hope for kids with rare bone disorder: new drug shows promise in Long-Term trial
Disease control By invitation onlyThis study is for children with hypochondroplasia, a condition that causes short stature and bone differences. Researchers are testing a drug called infigratinib to see if it is safe and helps improve growth over the long term. Participants must have already completed a previous …
Phase 2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a daily pill boost growth in kids with hypochondroplasia?
Disease control By invitation onlyThis study tests an oral drug called infigratinib in children with hypochondroplasia, a condition that causes short stature. The trial has two parts: first, all children receive the drug to see if it safely increases their growth rate; then, some will switch to a placebo to confi…
Phase 2/3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New oral drug shows promise for helping children with dwarfism grow
Disease control By invitation onlyThis study tests a daily oral drug called infigratinib in 300 children with achondroplasia, the most common form of dwarfism. The drug aims to improve bone growth by targeting a specific protein. Researchers will monitor safety and growth over several years, including children wh…
Phase 2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC